EU Launches New Response Body To Tackle Future Health Emergencies
HERA To Boost New Vaccines & Therapeutic Development, Clinical Trials & Manufacturing
Executive Summary
The European Commission has dismissed concerns about the operation of its new emergency response body, saying it will ensure the EU is well prepared for tackling future pandemics and other threats. HERA will complement, not duplicate, work conducted by existing agencies such as the European Medicines Agency, delegates heard at this week’s European Health Forum Gastein virtual conference.
You may also be interested in...
EU’s New Health Crisis Response Body ‘Won’t Duplicate’ Work Of EMA And ECDC
The directors of two key EU agencies outlined how they would work with the new HERA, and how they see their new roles under draft legislation aimed at strengthening their responses to health crises, at the recent European Health Forum Gastein conference. The European Medicines Agency also flagged up the potential role of real-world evidence in monitoring the safety and effectiveness of COVID-19 vaccines.
EU Wants Pharma To Offer ‘Ever-Warm’ Vaccine & Drug Production Capacity
As part of its efforts to bolster Europe’s readiness for health emergencies, the European Commission wants to make sure that additional production capacity is available at short notice.
European Commission Steps Further Towards ‘Ambitious’ Pharma Legislation Reform
The incentives system, access to medicines, future proofing for novel products and antimicrobial resistance are just some of the topics included in a new consultation.